A Study of Ficlatuzumab With HiDAC and HiDAC Alone in Adults With Relapsed or Refractory Acute Myeloid Leukemia (CyFi2)

A Phase 2, Randomized, Open-Label, Multicenter Study of Ficlatuzumab in Combination With High-Dose Cytarabine (HiDAC) and HiDAC Alone in Adults With Relapsed or Refractory Acute Myeloid Leukemia (AML)

This is a Phase 2, randomized, open-label, multicenter study to evaluate the safety and efficacy of ficlatuzumab in combination with high-dose cytarabine (HiDAC) and HiDAC alone in subjects with relapsed or refractory acute myeloid leukemia.

Study Overview

• Status: Withdrawn
• Conditions: Acute Myeloid Leukemia
• Intervention / Treatment: Biological: Ficlatuzumab; Drug: Cytarabine

• Study Type: Interventional
• Phase: Phase 2

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years and older (Adult, Older Adult)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

Description

Inclusion Criteria:

1. Diagnosis of AML according to the WHO criteria, which defines relapsed or refractory to induction therapy as follows:

   1. First relapse within 12 months after date of first CR or CRi
   2. Persistent AML documented by bone marrow biopsy at least 29 days after Day 1 of the first induction cycle of cytotoxic chemotherapy
   3. Hypercellular bone marrow with greater than 20% cellularity and 10% blasts at least 14 days after the first induction cycle Day 1
2. Age ≥18 years
3. Prior induction therapy, consisting of no more than 2 cycles of cytotoxic chemotherapy with at least one of the cycles consisting of anthracycline and cytarabine with reasonable schedule/dose intensity according to the discretion of the Investigator
4. Histologically confirmed AML by hematopathology review performed within 4 weeks of study entry. Secondary AML due to progression of myelodysplastic syndrome or myeloproliferative neoplasms is acceptable for inclusion.
5. Prior treatment for myelodysplastic syndrome or myeloproliferative neoplasm with hypomethylating agent or targeted agent is acceptable for inclusion
6. Ejection fraction ≥40% by echocardiogram or multigated acquisition (MUGA) scan
7. Cytoreduction therapy with leukapheresis or hydroxyurea is allowed
8. Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1, or 2

9. Clinical laboratory values meeting the following criteria before Day 1 (Cycle 1, Day 1):

   1. An estimated glomerular filtration rate of ≥ 60mL/min based on Cockcroft-Gault equation calculated using serum creatinine levels
   2. Total bilirubin ≤2.0 mg/dL (≤3.0 mg/dL for subjects with known Gilbert's syndrome)
   3. Aspartate aminotransferase (AST) or ALT ≤2.5 × ULN, unless thought to be due to AML
   4. Activated partial thromboplastin time ≤1.5 × ULN and prothrombin time/international normalized ratio (PT/INR) ≤1.5 × ULN if not on anticoagulation therapy. Subjects receiving anticoagulation therapy with an agent such as warfarin or low-molecular weight heparin may be allowed to participate with the therapeutic range established before initiation of study treatment.
10. For female subjects of childbearing potential, documentation of negative serum pregnancy test before randomization
11. For female subjects of childbearing potential and male subjects whose sexual partners are of childbearing potential, agreement to use an effective method of contraception during the study and for at least 90 days after the last dose of ficlatuzumab. Effective birth control includes (a) intrauterine device plus 1 barrier method; (b) oral, implantable, or injectable contraceptive plus 1 barrier method; or (c) 2 barrier methods. Effective barrier methods are male or female condoms, diaphragms, and spermicides (creams or gels that contain a chemical to kill sperm).
12. Ability to give written informed consent and comply with protocol requirements

Exclusion Criteria:

1. History of severe allergic or anaphylactic reactions or hypersensitivity to recombinant proteins or excipients in the investigational agent or cytarabine
2. Acute promyelocytic leukemia (AML French-American-British classification M3)
3. More than 2 cycles of prior induction therapy for AML
4. Prior treatment with intermediate- or HiDAC (≥1 gm/m2)
5. Allogeneic or autologous hematopoietic cell transplantation within 90 days of study entry
6. Prior treatment with any other investigational drugs, biologics, or devices, within 4 weeks before Day 1
7. Active graft versus host disease or immunosuppression for prevention or treatment of graft versus host disease within 4 weeks of study entry
8. Chemotherapy or radiation therapy within 1 week before study entry, other than hypomethylating agents or hydroxyurea used for cytoreduction

9. Significant cardiovascular disease, including:

   1. Cardiac failure New York Heart Association class III or IV
   2. Myocardial infarction, severe or unstable angina within 6 months before Day 1
   3. History of serious ventricular arrhythmia (ie, ventricular tachycardia or ventricular fibrillation)
10. Significant thrombotic or embolic events within 3 months before Day 1 (significant thrombotic or embolic events include, but are not limited to, venous thromboembolism, stroke, or transient ischemic attack). Catheter-related thrombosis is not a cause for exclusion. Diagnosis of deep vein thrombosis or pulmonary embolism is allowed if it occurred >3 months before Day 1 and anticoagulation therapy is completed before Day 1.
11. Any other medical condition or psychiatric condition that, in the opinion of the Investigator, might interfere with the subject's participation in the trial or interfere with the interpretation of trial results
12. History of prior/concurrent malignancy whose natural history or ongoing treatment is expected to interfere with the safety or efficacy assessment of the intervention
13. Known seropositive or active HIV
14. Active hepatitis B or C infection
15. Uncontrolled systemic fungal, bacterial, or viral infections
16. For female subjects, pregnant or breastfeeding
17. Prior exposure to the investigational agent or anti-c-MET, or anti-HGF within 6 months before study entry

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: None (Open Label)

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: Ficlatuzumab with HiDAC; Ficlatuzumab 20 mg/kg intravenously (IV) on Days 1 and 15 in combination with cytarabine 2 g/m2 IV per day on Days 2 through 7. Up to two additional doses can be administered - on Day 29, or on Days 29 and 43, if prolonged myelosuppression is experienced.	Biological: Ficlatuzumab; Ficlatuzumab is a selective recombinant humanized hepatocyte growth factor (HGF) inhibitory immunoglobulin G subclass 1 monoclonal antibody which blocks the MET tyrosine kinase receptor.; Other Names: AV-299; Drug: Cytarabine; Cytarabine is a chemotherapy agent. Chemotherapy agents are medications that kill cancer cells.; Other Names: Ara-C; Arabinosylcytosine
Active Comparator: HiDAC alone; Cytarabine 2 g/m2 IV per day on Days 1 through 6	Drug: Cytarabine; Cytarabine is a chemotherapy agent. Chemotherapy agents are medications that kill cancer cells.; Other Names: Ara-C; Arabinosylcytosine

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Overall Response Rate (ORR)	To estimate the overall response rate (ORR) (complete remission [CR] + CR with incomplete hematologic recovery [CRi]) of ficlatuzumab in combination with high-dose cytarabine (HiDAC) and HiDAC alone in adults with relapsed or refractory acute myeloid leukemia (AML)	Approximately 13 months (through study treatment completion)

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Number of participants with treatment-related adverse events as assessed by CTCAE v5.0	To evaluate the safety and tolerability of ficlatuzumab when administered with HiDAC and HiDAC alone	Approximately 14 months (through 30 days after the last subject completes treatment)
Overall Survival (OS)	To estimate the overall survival (OS) rate of ficlatuzumab in combination with HiDAC and HiDAC alone in adults with relapsed or refractory AML	For up to one year after the end of study treatment
Disease-Free Survival (DFS)	To estimate the disease-free survival (DFS) rate of ficlatuzumab in combination with HiDAC and HiDAC alone in subjects achieving CR	For up to one year after the end of study treatment

Collaborators and Investigators

• Sponsor: AVEO Pharmaceuticals, Inc.
• Collaborators: Biodesix, Inc.

Study record dates

Study Major Dates

• Study Start (Anticipated): January 31, 2020
• Primary Completion (Actual): March 27, 2020
• Study Completion (Actual): March 27, 2020

Study Registration Dates

• First Submitted: September 12, 2019
• First Submitted That Met QC Criteria: September 20, 2019
• First Posted (Actual): September 24, 2019

Study Record Updates

• Last Update Posted (Actual): March 31, 2020
• Last Update Submitted That Met QC Criteria: March 27, 2020
• Last Verified: March 1, 2020

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Neoplasms by Histologic Type; Neoplasms; Leukemia; Leukemia, Myeloid; Leukemia, Myeloid, Acute; Physiological Effects of Drugs; Molecular Mechanisms of Pharmacological Action; Anti-Infective Agents; Antiviral Agents; Antimetabolites, Antineoplastic; Antimetabolites; Antineoplastic Agents; Immunosuppressive Agents; Immunologic Factors; Cytarabine
• Other Study ID Numbers: AV-299-19-207

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: Yes
• Studies a U.S. FDA-regulated device product: No